

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/TD1F96C4289EN.html>

Date: December 2019

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: TD1F96C4289EN

Abstracts

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

SUMMARY

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 8 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Solid Tumor, Autoimmune Disorders, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Adenoid Cystic Carcinoma (ACC), Arthritis, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Hepatitis B, Hepatocellular Carcinoma, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic

Colorectal Cancer, Osteoarthritis, Peritoneal Cancer, Rabies, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 8 (CD288 or TLR8) - Overview

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development

Altimune Inc

Ascendis Pharma A/S

BioNTech SE

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac AG

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

IngenoVax LLC

Janus Biotherapeutics Inc

Nektar Therapeutics

Resolve Therapeutics LLC

Seven and Eight Biopharmaceuticals Corp

Shanghai De Novo Pharmatech Co Ltd

Silverback Therapeutics Inc

Vaccex Inc

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles

ALT-702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUCPT-8m - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-8102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1508052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INGMM-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JB-6121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates to Agonize TLR7 and TLR8 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

motolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-262 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-6050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selgantolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize TLR7 and TLR8 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TLR7 and TLR8 for Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR8 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones

Featured News & Press Releases

Dec 12, 2019: Silverback Therapeutics announces preclinical data at 2019 San Antonio Breast Cancer Symposium (SABCS) supporting development of SBT6050 as a single agent and in combination with Trastuzumab for the treatment of HER2-expressing malignancies

Nov 09, 2019: Bolt Biotherapeutics presents preclinical data showing eradication of large resistant tumors with ISAC monotherapy at SITC 2019

Nov 06, 2019: Ascendis Pharma announces first presentation of preclinical data utilizing TransCon Technology in Oncology at SITC 2019

Nov 05, 2019: Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050's Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint Inhibition

Nov 05, 2019: Bolt Biotherapeutics announces ISAC data presentation At the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 24, 2019: CureVac to present CV8102 data at SITC Conference

Jul 22, 2019: Resolve Therapeutics announces completion of enrollment for phase 2a study of RSLV-132 for the treatment of lupus

Jul 02, 2019: Vaccex provides update on development of VX001

Jun 13, 2019: Resolve Therapeutics announces RSLV-132 significantly reduces fatigue in phase II study of patients with sjogrens syndrome

Jun 13, 2019: CureVac receives grants for three patents regarding intratumoral application of RNA

Jun 10, 2019: Resolve Therapeutics to Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

Jun 05, 2019: Altimune announces important additions to its patent portfolio for ALT-702 Program

Apr 11, 2019: Gilead presents on its Hepatitis B drug candidate GS-9688 at the International Liver Congress 2019

Apr 01, 2019: Bolt Biotherapeutics presents preclinical proof of concept data at American Association for Cancer Research (AACR) Conference

Mar 21, 2019: CureVac announces late-breaking poster presentation at American Association of Cancer Research (AACR) Annual Meeting 2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Altimune Inc, H2 2019
Pipeline by Ascendis Pharma A/S, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Bolt Biotherapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Curebiotech Inc, H2 2019
Pipeline by Curevac AG, H2 2019
Pipeline by Dynavax Technologies Corp, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Galderma SA, H2 2019
Pipeline by Gilead Sciences Inc, H2 2019
Pipeline by IngenoVax LLC, H2 2019
Pipeline by Janus Biotherapeutics Inc, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Resolve Therapeutics LLC, H2 2019
Pipeline by Seven and Eight Biopharmaceuticals Corp, H2 2019
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H2 2019
Pipeline by Silverback Therapeutics Inc, H2 2019
Pipeline by Vaccex Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Altimune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Ingenovax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc

I would like to order

Product name: Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/TD1F96C4289EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TD1F96C4289EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970